Harminder Paul - Publications

Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 01, 2022

Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: September 14, 2021

Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains.

Journal: European journal of haematology

Published: July 28, 2021

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Journal: Leukemia & lymphoma

Published: January 29, 2021

Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 17, 2020

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.

Journal: Leukemia & lymphoma

Published: June 02, 2020

A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).

Journal: Leukemia & lymphoma

Published: October 03, 2018

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).

Journal: Leukemia & lymphoma

Published: June 20, 2018

Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: March 12, 2014